Colorectal Cancer Liver Metastasis, Stage III Colorectal Cancer
Conditions
Brief summary
The main purpose of this research is to verify the safety of CEA targeted chimeric antigen receptor T cells and to determine the proper dosage of CAR T cells infused.
Detailed description
Chimeric antigen receptor (CAR)-modified T cells have demonstrated great successes in treating even late stage cluster of differentiation antigen 19 (CD19) positive B cell malignancies. But it has few studies in solid tumors. The carcino-embryonic antigen(CEA) is widely expressed in cancers like gastric cancer, lung cancer, pancreatic cancer, breast cancer and colorectal cancer. To confirm if CAR T cells still function in solid tumors, we have developed anti-CEA CAR-modified T cells. Preclinical studies have demonstrated effective killing of CEA target cells. In this study, the CEA CARs, will be evaluated in CEA positive gastric cancer. The primary goal is to confirm its adverse effects including cytokine storm response and any other adverse effects. In addition, tumor targeting and disease status after treatment will also be evaluated.
Interventions
BIOLOGICALAnti-CEA-CAR T
T cells modified with CEA targeted chimeric antigen receptor.
Sponsors
HuaDao (Shanghai) Biomedical Co., Ltd.
Ruijin Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. CEA positive T4/N2 high-risk stage-Ⅲ colorectal cancer after surgery or patients with colorectal cancer liver metastasis after R0 surgery; 2. Patients whose serum CEA ≥11 ng/mL; 3. Life expectancy ≥ 3 months; 4. PS score 0-2, KPS score ≥60; 5. \>3 CTC/7.5 mL blood sample; 6. Patients who plan to use XELOX chemotherapy after surgery; 7. Patients must have adequate organ function , such as NYHA heart function classification grade III or higher, no severe anemia, hypoxia; liver function: total bilirubin ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN when liver metastasis), ALT≤2.5×ULN, AST≤2.5×ULN (ALT or/and AST≤5×ULN when liver metastasis); renal function: blood creatinine ≤1.5 × ULN and creatinine clearance ≥50 mL/min, only when blood creatinine ≤ Calculate the creatinine clearance rate when 1.5 × ULN; 8. Sufficient peripheral blood can be obtained through peripheral veins without contraindications to apheresis; 9. Patients of childbearing age have no birth plans and take effective contraceptive measures during the study period and within 1 year after the study.
Exclusion criteria
1. Patients who have a history of severe central nervous system disease; 2. Other organ metastases except liver; 3. Patients who have non malignant diseases, including autoimmune diseases, primary immunodeficiency diseases or obstructive or restrictive respiratory diseases; 4. Patients received car-t or other gene modified T cell therapy previously; 5. Patients who plan to use other targeted anti-tumor drugs; 6. Patients who participated in other clinical studies within 30 days before screening or planned to participate in other clinical studies during the study period; 7. Patients who have syphilis or HIV / HBV / HCV / HPV / EBV / CMV infection ; HBV-DNA copy number ≥ 1 × 10 \^ 5 copies / ml is required for HBV seropositive patients; 8. Patients who have uncontrollable systemic infectious diseases; 9. Patients who have multiple malignant tumor; 10. Patients who received or may need Chinese herbal medicine, systemic glucocorticoid or other immunosuppressants within 2 weeks before enrollment; 11. Patient who are pregnancy and lactating; 12. Patients who have severe gastroduodenal ulcer, ulcerative colitis and other intestinal inflammation;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events that related to treatment | 4 weeks | Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival time of Anti-CEA CAR T cells in vivo. | 3 months | To evaluate the presence of circulating CAR T cells with flow cytometry and real time PCR in patient blood. |
| Efficacy of anti-CEA CAR T cells to confirm the ability of CAR T cells to kill CEA positive cancer cells | 6 months | To evaluate the presence of circulating tumor cells with flow cytometry and real time PCR in patient blood. |
| Maximum tolerated dose (MTD) of CEA targeted CAR T cells | 4 weeks | To confirm the maximum tolerated dose of CEA targeted CAR T cells. |
Contacts
Primary ContactMei Wang, Medical PhD
Backup ContactLin Tian, Medical PhD
Outcome results
None listed